CD274 and small cell lung carcinoma: In recent years, immunotherapy has emerged as a potential breakthrough, with immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 and CTLA‐4 pathways showing promise in improving survival for some ES‐SCLC patients.